Clarius Mobile Health, a global provider of AI-enabled handheld ultrasound technology, has reported a landmark year marked by profitability and strong growth in fiscal year 2025. The company closed the year with approximately 20 percent growth, reflecting the success of its long-term business transformation and reinforcing its position as a durable competitor in the medical imaging market. This performance signals a shift from rapid expansion to sustainable operations while continuing to invest in innovation.
Health Technology Insights: Jackson Choy Joins Match Health as Co-Founder, Pulse President
Laurent Pelissier, Chief Executive Officer of Clarius Mobile Health, described 2025 as a defining moment for the company. He explained that Clarius brought together disciplined execution with a strong focus on clinically validated innovation. According to Pelissier, reaching profitability while introducing new FDA-cleared AI technologies shows that the company is building a stable future for handheld ultrasound and supporting broader adoption of advanced imaging in everyday clinical practice.
Throughout 2025, Clarius strengthened its leadership in artificial intelligence for point-of-care ultrasound. The company introduced two newly FDA-cleared AI models within the Clarius Ultrasound App, bringing the total number of FDA-cleared models to six. In parallel, the total number of deployed AI technologies reached sixteen, spanning education, diagnostics, and workflow support. Among these innovations, Clarius Prostate AI automatically identifies the prostate and performs precise measurements to calculate prostate volume and PSA density for urology assessments. Clarius Median Nerve AI supports clinicians by locating and measuring the median nerve during evaluations for carpal tunnel syndrome. These advancements further established Clarius as a leader in practical and clinically relevant AI solutions.
Clarius also gained significant global recognition for its work in medical imaging. In 2025, the company was named to TIME’s list of the World’s Top HealthTech Companies, earning a leading position in the Medical Devices and Wearables category. This acknowledgment highlighted the company’s impact on modernizing diagnostic imaging and expanding access to advanced ultrasound technology.
Health Technology Insights: Lifeward Expands ReWalk Exoskeleton Distribution Globally
International growth remained a major focus. Clarius expanded its distribution footprint to reach healthcare providers in more than seventy countries. The company also reported doubled growth across the Indo-Pacific region, reflecting rising demand for portable and AI-powered imaging solutions. In Canada, Clarius was selected as one of only eight companies to participate in the national Global Hypergrowth Program, further supporting its international expansion strategy.
In addition to clinical markets, Clarius broadened its business-to-business ecosystem by entering strategic collaborations with pharmaceutical companies and contract research organizations. These partnerships positioned Clarius handheld ultrasound systems as reliable tools for evidence-based research in drug development and patient care. Through their use in structured clinical trials, the company opened new revenue channels while validating the role of portable ultrasound in research environments.
Product development remained active throughout the year. Clarius delivered more than sixty new features across four major software releases in 2025. Enhancements included expanded T-Mode capabilities for breast, shoulder, and abdominal imaging, along with the introduction of Auto Preset AI designed specifically for veterinary applications. These updates improved usability and broadened the scope of clinical and non-clinical use cases.
The company also invested heavily in education and professional engagement. Clarius participated in more than eighty medical trade shows worldwide and hosted fifteen clinical webinars aimed at healthcare professionals. Its education partner network grew to twenty-nine organizations globally, supporting Clarius’s mission to improve ultrasound training and accessibility across regions.
Looking toward 2026, Clarius plans to build on its financial stability and growing momentum. The company remains focused on advancing its AI portfolio, strengthening industry partnerships, and delivering affordable, easy-to-use, high-quality ultrasound solutions to healthcare providers around the world.
Health Technology Insights: LifeSci Communications Promotes Ian Stone to Chief Executive Officer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
